Stock Financial Ratios, Dividends, Split History

CVTI / Covenant Transportation Group, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price30.60
Volume96,100.00
Market Cap ($M)69.84
Enterprise Value ($M)242.87
Book Value ($M)301.69
Book Value / Share128.38
Price / Book0.23
NCAV ($M)-181.86
NCAV / Share-77.39
Price / NCAV-0.39
Share Statistics
Common Shares Outstanding 15,980,825
Weighted Average Number Of Diluted Shares Outstanding 18,372,000
Weighted Average Number Of Shares Outstanding Basic 18,279,000
Common Shares Outstanding2 2,350,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.09
Return on Equity (ROE)0.23
Balance Sheet (mrq) ($M)
Assets655.33
Liabilities353.64
Quick Ration/a
Current Ratio2.18
Income Statement (mra) ($M)
Revenues705,007,000.00
Cargo And Freight Revenue626,809,000.00
Revenue Equipment Rentals And Purchased Transportation141,954,000.00
Reimbursement Revenue78,198,000.00
Operating Income28.16
Net Income55.44
Earnings Per Share Basic3.03
Earnings Per Share Diluted3.02
Cash Flow Statement (mra) ($M)
Cash From Operations82.85
Cash from Investing-62.05
Cash from Financing-62.05
Identifiers and Descriptors
CUSIP22284P105
Central Index Key (CIK)928658

Split History

Stock splits are used by Covenant Transportation Group, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Zacks.com featured highlights include: GMS, Covenant Transportation, Domtar, Darling Ingredients and MGM

2018-07-16 zacks
Chicago, IL – July 16, 2018 - Stocks in this week’s article GMS Inc. (GMS - Free Report) , Covenant Transportation Group, Inc. (CVTI - Free Report) , Domtar Corp. (UFS - Free Report) , Darling Ingredients Inc. (DAR - Free Report) and MGM Growth Properties LLC (MGP - Free Report) . (16-0)

5 Value Picks Flaunting Impressive EV/EBITDA Ratios

2018-07-13 zacks
Investors typically have a fixation on the price-to-earnings (P/E) multiple, while seeking stocks that are trading at bargain prices. This straight-forward, easy-to-calculate ratio is the most-preferred one among valuation metrics in the investment toolkit for working out the fair market value of a stock. But even this widely used valuation metric is not without its shortcomings. EV/EBITDA is a Better Alternative, But Why? While P/E enjoys great popularity, a less-used and more-complicated metric called EV/EBITDA gains an upper hand as it offers a clearer image of a company’s valuation and earnings potential. (5-1)

The Zacks Analyst Blog Highlights: First Financial Northwest, Northern Oil and Gas, Echo Global Logistics, RCI Hospitality Holdings and Covenant Transportation Group

2018-07-09 zacks
Chicago, IL – July 9, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include First Financial Northwest, Inc. (FFNW - Free Report) , Northern Oil and Gas, Inc. (NOG - Free Report) , Echo Global Logistics, Inc. (ECHO - Free Report) , RCI Hospitality Holdings, Inc. (35-1)

Think Small As U.S.-China Trade War Breaks Out! 5 Top Picks

2018-07-06 zacks
The United States and China have imposed tit-for-tat tariffs on each other’s imports, with Beijing accusing the United States for triggering the ‘largest scale trade war’. Corporates, undoubtedly, are fretting over the risks a trade war will pose to their earnings. (16-1)

5 Top-Ranked Small-Cap Stocks to Survive 2H

2018-07-05 zacks
Small-cap stocks have been enjoying a stellar 2018, when their larger counterparts are suffering from simmering trade tensions. The Russell 2000 gained 7% in 1H18, significantly more than the S&P 500, which advanced only 1.7% over this period. (14-3)

CUSIP: 22284P105